AR087445A1 - Metodo para establecer el riesgo de enfermedad cardiovascular - Google Patents

Metodo para establecer el riesgo de enfermedad cardiovascular

Info

Publication number
AR087445A1
AR087445A1 ARP120102838A ARP120102838A AR087445A1 AR 087445 A1 AR087445 A1 AR 087445A1 AR P120102838 A ARP120102838 A AR P120102838A AR P120102838 A ARP120102838 A AR P120102838A AR 087445 A1 AR087445 A1 AR 087445A1
Authority
AR
Argentina
Prior art keywords
seq
risk
subject
cardiovascular
assessment
Prior art date
Application number
ARP120102838A
Other languages
English (en)
Inventor
De La Iglesia Jaume Marrugat
Llanos Roberto Elosua
Gomez Joan Salgado
Perez-Rasilla Eduardo Salas
Fernandez Sergio Castillo
Muoz Jose Maria Ordovas
Original Assignee
Gendiag Exe Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gendiag Exe Sl filed Critical Gendiag Exe Sl
Publication of AR087445A1 publication Critical patent/AR087445A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a un método para la reclasificación de un sujeto para una evaluación del riesgo más apropiada que la obtenida usando los algoritmos para esa estimación de riesgos tal como, pero no limitada a, Framingham, Regicor, Score, Procamor, Qrisk, basada en la presencia de diferentes polimorfismos. También se refiere a un método para determinar el riesgo de padecer una enfermedad cardiovascular combinando la ausencia o la presencia de uno o más marcadores polimórficos en una muestra del sujeto con factores de riesgo convencionales para CVD así como también medios implementados por computadora para llevar a cabo dicho método.Reivindicación 1: Un método para una evaluación del riesgo cardiovascular en un sujeto, o para una reclasificación de un sujeto a una evaluación mejorada del riesgo en comparación con la obtenida usando las escalas/los métodos para tal estimación de riesgo, tales como, pero no limitados a, Framingham, Regicor, Score, Procamor, Qrisk, caracterizado porque comprende los pasos de determinar en una muestra aislada de dicho sujeto la presencia de polimorfismos en las posiciones 27 dentro de las secuencias de ácidos nucleicos de SEQ ID Nº 1 a 34, en donde la presencia en la posición 27 de una C en la SEQ ID Nº 1, C en la SEQ ID Nº 2, T en la SEQ ID Nº 3, C en la SEQ ID Nº 4, C en la SEQ ID Nº 5, C en la SEQ ID Nº 6, T en la SEQ ID Nº 7, G en la SEQ ID Nº 8, A en la SEQ ID Nº 9, A en la SEQ ID Nº 10, A en la SEQ ID Nº 11, G en la SEQ ID Nº 12, A en la SEQ ID Nº 13, C en la SEQ ID Nº 14, G en la SEQ ID Nº 15, A en la SEQ ID Nº 16, A en la SEQ ID Nº 17, G en la SEQ ID Nº 18, C en la SEQ ID Nº 19, T en la SEQ ID Nº 20, A en la SEQ ID Nº 21, G en la SEQ ID Nº 22, C en la SEQ ID Nº 23, C en la SEQ ID Nº 24, G en la SEQ ID Nº 25, C en la SEQ ID Nº 26, A en la SEQ ID Nº 27, C en la SEQ ID Nº 28, G en la SEQ ID Nº 29, T en la SEQ ID Nº 30, T en la SEQ ID Nº 31, C en la SEQ ID Nº 32, C en la SEQ ID Nº 33 y/o C en la SEQ ID Nº 34 es indicativa de un riesgo de tener un evento cardiovascular.
ARP120102838A 2011-08-05 2012-08-03 Metodo para establecer el riesgo de enfermedad cardiovascular AR087445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11176695.2A EP2554679B1 (en) 2011-08-05 2011-08-05 Genetic markers for cardiovascular disease risk assessment

Publications (1)

Publication Number Publication Date
AR087445A1 true AR087445A1 (es) 2014-03-26

Family

ID=46604315

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102838A AR087445A1 (es) 2011-08-05 2012-08-03 Metodo para establecer el riesgo de enfermedad cardiovascular

Country Status (14)

Country Link
US (1) US11814673B2 (es)
EP (2) EP2554679B1 (es)
AR (1) AR087445A1 (es)
BR (1) BR112014002856A2 (es)
CA (1) CA2844103C (es)
DK (1) DK2554679T3 (es)
ES (2) ES2573648T3 (es)
HU (1) HUE029534T2 (es)
MX (1) MX356640B (es)
PL (1) PL2554679T3 (es)
PT (1) PT2739750T (es)
SA (1) SA112330754B1 (es)
UY (1) UY34243A (es)
WO (1) WO2013020870A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2843056B8 (en) * 2013-08-30 2019-06-26 GENINCODE UK, Ltd. Risk markers for cardiovascular disease in patients with chronic kidney disease
US10704097B2 (en) 2014-02-27 2020-07-07 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
EP3110973B1 (en) * 2014-02-27 2019-02-06 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
US20190295727A1 (en) * 2018-03-23 2019-09-26 American Heart Association, Inc. System and Method for Assessing Heart Health and Communicating the Assessment to a Patient
CN110840891A (zh) * 2018-08-20 2020-02-28 山西医科大学 降压药潘必定（Pempidine）可作为新型抗心律失常药物
CN111354464B (zh) * 2018-12-24 2024-05-17 深圳先进技术研究院 Cad预测模型建立方法、装置以及电子设备
CN109859847A (zh) * 2019-02-15 2019-06-07 京东方科技集团股份有限公司 电子设备、体重管理收益预测装置及存储介质
WO2021185936A1 (en) 2020-03-17 2021-09-23 Chen Zhao System and method for generating personalized treatments
KR20230092953A (ko) * 2020-10-20 2023-06-26 지네틱 테크놀로지스 리미티드 질병 발병의 위험을 평가하는 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6159693A (en) 1998-03-13 2000-12-12 Promega Corporation Nucleic acid detection
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
CA2558458A1 (en) * 2004-03-05 2005-09-22 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
MX2009008878A (es) 2007-02-21 2009-08-28 Decode Genetics Ehf Variantes de susceptibilidad genetica asociada con la enfermedad cardiovascular.
US20110014613A1 (en) * 2009-04-01 2011-01-20 Pfuetzner-Riehn Elisabeth Genotyping for Risk of Atherosclerosis
ES2623633T3 (es) * 2009-06-09 2017-07-11 Gendiag.Exe, S.L. Marcadores de riesgo para enfermedad cardiovascular
US20110269735A1 (en) * 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Also Published As

Publication number Publication date
WO2013020870A1 (en) 2013-02-14
ES2573648T3 (es) 2016-06-09
EP2739750A1 (en) 2014-06-11
WO2013020870A4 (en) 2013-04-25
SA112330754B1 (ar) 2015-11-08
CA2844103A1 (en) 2013-02-14
EP2554679A1 (en) 2013-02-06
EP2739750B1 (en) 2017-11-15
ES2657746T3 (es) 2018-03-06
US11814673B2 (en) 2023-11-14
US20140342355A1 (en) 2014-11-20
BR112014002856A2 (pt) 2017-02-21
MX2014001463A (es) 2014-05-14
CA2844103C (en) 2019-03-12
DK2554679T3 (en) 2016-04-04
UY34243A (es) 2013-02-28
PT2739750T (pt) 2018-02-13
MX356640B (es) 2018-06-07
PL2554679T3 (pl) 2016-09-30
HUE029534T2 (hu) 2017-02-28
EP2554679B1 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
AR087445A1 (es) Metodo para establecer el riesgo de enfermedad cardiovascular
MX2011013243A (es) Marcadores de riesgo para enfermedad cardiovascular.
GB201317477D0 (en) Methods, compositions and kits for determing the presence/absnece of a variant nucleic acid sequence
MY172864A (en) Noninvasive detection of fetal genetic abnormality
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
MX2019015159A (es) Composiciones, metodos y usos para asistir en el diagnostico, pronostico y tratamiento de la fibrosis pulmonar idiopatica.
WO2014116729A3 (en) Haplotying of hla loci with ultra-deep shotgun sequencing
EA201590027A1 (ru) Способы детекции заболеваний или состояний
MX341840B (es) Biomarcadores de microarn indicativos de la enfermedad de alzheimer.
MX2022014633A (es) Metodos para detectar norovirus.
EP2799556A3 (en) Thromboembolic disease
MX2018014163A (es) Composiciones de nucleotido marcados y metodos para el secuenciamiento de acido nucleico.
UY35075A (es) Biomarcadores predictivos de la respuesta clínica al acetato de glatirámero
AR097489A1 (es) Marcadores de riesgo para cardiovasculopatías en pacientes con nefropatía crónica
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
ITMI20111344A1 (it) Metodo di tintura reattiva di pelle
MX2014006811A (es) Metodo para el diagnostico y/o pronostico de daño renal agudo.
EA201491463A1 (ru) Способ получения соединения по новой реакции присоединения михаэля с применением воды или различных кислот в качестве добавки
ES2634763T3 (es) Enzimas para la transformación de ergopeptinas así como un procedimiento para ello
ES2671745T3 (es) Detección de Neisseria gonorrhoeae
EP2562267A3 (en) Method and kit for identifying Phalaenopsis varieties
WO2014110230A3 (en) Methods for diagnosing cancer based on small nucleolar rna hbii-52
EA201790642A1 (ru) Аллель-специфическая терапия для гаплотипов болезни хантингтона
UA105909U (uk) Спосіб прогнозування активності цитологічного синдрому у хворих на неалкогольну жирову хворобу печінки з урахуванням поліморфізму гена глутатіон-s-трансферази
Novosad THE MODERN ISSUES OF ENERGY PRICING

Legal Events

Date Code Title Description
FB Suspension of granting procedure